NEW YORK — Merck, the second-biggest U.S. drugmaker, narrowed its full-year forecast as the company continues an overhaul of its sales and research operations.
Profit for 2013 will be $3.48 to $3.52 a share, Merck said Monday in a statement. The previous outlook was for $3.45 to $3.55. Chief Executive Officer Ken Frazier said he is still looking at whether Whitehouse Station, N.J.-based Mercks animal health and consumer businesses, as well as its drug projects, might be divested or partnered outside the company.
A company is a living, breathing thing, and over time one has to evaluate the opportunities going forward, Frazier said in an interview Monday. The question becomes, are we the right owner of those businesses?
Merck this month announced it would fire 8,500 workers and overhaul research and development. The firings add to 7,500 job cuts already announced, amounting to a 20 percent reduction in Mercks workforce. The company had about 80,000 employees as of Sept. 30.
Merck employs about 1,800 people in North Carolina, including 1,100 at a vaccine manufacturing plant in Durham and 450 at a packaging plant in Wilson. The company has declined to break down where the job cuts will occur.
Drugmakers have been cutting expenses, research programs and positions to focus on creating new medicines, as well as selling or splitting off non-pharmaceutical businesses.
Mercks changes are about focus, not slashing expenses, Frazier said. Merck is and will remain committed to investing in R&D internally, and importantly, externally, he said. Its about precision, its about focus, its not about reduction.
Merck shares declined 2.6 percent to close at $45.35 on Monday. The company has struggled to keep investor support, with its stock falling 1.7 percent in the last 12 months, compared with a 23 percent gain in the Standard & Poors 500 Pharmaceuticals Index.
Third-quarter revenue fell 4 percent to $11 billion, missing the $11.1 billion estimate of analysts, as Januvia sales dropped 5 percent and foreign currency exchange weighed on results.
Januvia/Janumet widely missed consensus, said Mark Schoenebaum, an analyst with International Strategy & Investment Group, in a note to clients. We would expect the company to back off its prior guidance to expect mid-single digit year-on-year Januvia franchise growth.
Net income dropped to $1.12 billion, or 38 cents a share, from $1.73 billion, or 56 cents, a year earlier, the company said. Earnings, excluding one-time items, were 92 cents a share, beating by 5 cents the average of 17 analysts estimates compiled by Bloomberg.
Merck sentiment continues to get really bad, Schoenebaum said. Ive become increasingly frustrated with fighting this management discount.
Merck shareholders have been most concerned that sales of Januvia, its diabetes treatment, will face more competition, said Tony Butler, an analyst with Barclays Plc. Third-quarter sales of Januvia fell to $927 million from a year earlier.
Half-a-dozen new treatments that could compete with Januvia may begin selling in the next two years. The medicine has already experienced most of its potential growth, while competitors are cutting prices and marketing harder, Butler said. Both volume and pricing opportunities for Januvia/Janumet are limited going forward, he said in a note to clients this month.
Under new R&D chief Roger Perlmutter, Merck is overhauling its research labs to put more emphasis on vaccines, cancer, diabetes and hospital care. The moves will save $2.5 billion a year by 2015, according to the company.
Perlmutter said Monday he was displeased with the quality of the companys R&D efforts, particularly with submissions to U.S. regulators.
Im not happy with where we stand in terms of how our organization has been able to deliver documents that meet regulatory guidelines, Perlmutter said on the call. I have been leaning into this process very, very heavily. He planned to hire a new head of global safety, as well as make additional hires to improve the safety and quality of the companys clinical trials.